Journal
ONCOTARGET
Volume 7, Issue 41, Pages 67532-67550Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11376
Keywords
PRMT; JMJD6; methylation; demethylation; cancer
Categories
Funding
- La Ligue contre le Cancer
- Fondation ARC CANCER
- NIH [DK055274]
Ask authors/readers for more resources
Protein arginine methylation is a common post-translational modification involved in numerous cellular processes including transcription, DNA repair, mRNA splicing and signal transduction. Currently, there are nine known members of the protein arginine methyltransferase (PRMT) family, but only one arginine demethylase has been identified, namely the Jumonji domain-containing 6 (JMJD6). Although its demethylase activity was initially challenged, its dual activity as an arginine demethylase and a lysine hydroxylase is now recognized. Interestingly, a growing number of substrates for arginine methylation and demethylation play key roles in tumorigenesis. Though alterations in the sequence of these enzymes have not been identified in cancer, their overexpression is associated with various cancers, suggesting that they could constitute targets for therapeutic strategies. In this review, we present the recent knowledge of the involvement of PRMTs and JMJD6 in tumorigenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available